Child part of a TEVA Pediatric Chronic Migraine Prevention clinical trial  

LYNN HEALTH SCIENCE INSTITUTE IS LOOKING FOR PARTICIPANTS

PAID CLINICAL TRIAL

  • Lasting 4 weeks to 1 year.
  • 7 Clinic Visits 

YOU MAY BE ELIGIBLE TO PARTICIPATE IF YOU MEET THE FOLLOWING CRITERIA:

  • Male or Female 6-17 years to  years old
  • Have 4 to 14 migraines attacks per month with moderate to severe headache
Migraine is typically characterized by attacks of throbbing, headache of moderate or severe pain intensity, associated with nausea, vomiting, and/or sensitivity to light (photophobia), and sound (phonophobia). In approximately 25% of individuals, the migraine headache is preceded by focal neurological dysfunction (aura), and the presence of aura increases in pediatric patients as they get older. Improving diagnosis and optimizing treatments for migraine have been recognized as critically important to overcoming current barriers to reduce the global burden of migraine. The majority of medications utilized for the preventive treatment of migraine in children and adolescent patients are prescribed off-label due to the limited number of approved therapies. Thus, there is a significant clinical need for additional therapeutic agents for the treatment of migraine in children and adolescents.